Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM, Cascavilla N, Dell'Olio M, La Sala A, Mantuano S, Melillo L, Nobile M, Scalzulli PR, Bisceglia M, Carella AM. Musto P, et al. Among authors: carella am. Leuk Lymphoma. 2004 Jun;45(6):1219-22. doi: 10.1080/10428190310001641143. Leuk Lymphoma. 2004. PMID: 15360005
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A. Musto P, et al. Among authors: carella am jr, carella am. Leuk Res. 2006 Mar;30(3):283-5. doi: 10.1016/j.leukres.2005.06.027. Epub 2005 Aug 18. Leuk Res. 2006. PMID: 16111749 Free article. Clinical Trial.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Musso M, et al. Among authors: carella am. Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26458240 Free PMC article.
Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.
Musto P, Carella AM Jr, Greco MM, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, Carella AM. Musto P, et al. Among authors: carella am jr, carella am. Br J Haematol. 2003 Nov;123(4):746-7. doi: 10.1046/j.1365-2141.2003.04675.x. Br J Haematol. 2003. PMID: 14616983 Free article. Clinical Trial. No abstract available.
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, Balocco M, Michelis G, Miglino M, Manna A, Balleari E, Carella AM, Sessarego M, Van Lint MT, Bacigalupo A, Gobbi M. Clavio M, et al. Among authors: carella am. Br J Haematol. 2007 Jul;138(2):186-95. doi: 10.1111/j.1365-2141.2007.06646.x. Br J Haematol. 2007. PMID: 17593025 Free article. Clinical Trial.
330 results